Compare AURE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURE | SCYX |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | Hong Kong | United States |
| Employees | 4 | 29 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 60.4M |
| IPO Year | N/A | 2014 |
| Metric | AURE | SCYX |
|---|---|---|
| Price | $2.50 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 51.1K | ★ 344.2K |
| Earning Date | 06-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.57 |
| 52 Week High | $3.53 | $1.29 |
| Indicator | AURE | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 30.24 |
| Support Level | $2.33 | $0.67 |
| Resistance Level | $2.70 | $0.70 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.44 | 12.44 |
Aurelion Inc is a Tether Gold (XAUT) Real World Asset (RWA) company focused on developing a business around tokenized gold. XAUT combines the stability of physical gold with the efficiency of blockchain, providing investors access to a tokenized gold reserve that could serve as a haven to inflation, currency devaluation, and crypto volatility. In parallel to building a business around the development of tokenized gold, Aurelion provides wealth management and asset management services.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.